Abstract
Efficacy and Safety of Romiplostim in Patients with Acquired Aplastic Anemia Ineligible or Refractory to Immunosuppressive Therapy: Interim Analysis of Phase 2/3 Clinical Trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have